ClinicalTrials.gg
RecruitingNCT04495881Updated Jul 28, 2023

Sitagliptin for the Treatment of Type 2 Diabetes

A Phase 4 interventional study of Sitagliptin 100mg in Type 2 Diabetes, sponsored by Beijing Chao Yang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Beijing Chao Yang Hospital · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jan 2020, registered Jul 2020).
  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Planned enrollment
132nd of 197
50 · median 102
Started
2020
with 4 others
Phase 4
68 of 198
3 open now
Registered
187th of 198
by date

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 132nd largest by planned enrollment of the 197 interventional ones that give a count, is one of 5 that started in 2020, is one of 68 in phase 4, and was the 187th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Patients newly diagnosed with T2D will be recruited and will receive sitagliptin treatment for 3 months. The gut microbiome of the participants before and after the treatment and the effectiveness of sitagliptin treatment on type 2 diabetes will be evaluated.

Read the detailed description

The dipeptidyl peptidase-4 inhibitor sitagliptin is a classic anti-diabetic drug(1) and is widely applied to both scientific research and clinical trial(2-6). This clinical trial aims to study the effectiveness of sitagliptin treatment in T2D patients and related change of gut microbiome. 50 Patients newly diagnosed with T2D will be recruited. With patient's informed consent, patient-related vital signs (such as age, height, weight, body mass index), laboratory indicators (including glycated hemoglobin, glycated albumin, low-density lipoprotein, total cholesterol, triglycerides), fasting blood glucose, insulin levels and Insulin resistance index (HOMA-IR)(7) will be recorded and analyzed. The feces of the patients will be collected to analyze the gut microbiome. All of the patients will receive the sitagliptin treatment for 3 months. The gut microbiome of the patients and the effectiveness of sitagliptin treatment on diabetes will be evaluated at indicated times during follow-up.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18-65 years old newly diagnosed with type 2 diabetes
  • ≥ 7%

Exclusion criteria

Exclusion Criteria:

  • The positive of diabetes antibodies
  • Anti-diabetic drugs therapy before participation
  • Pancreatitis
  • Coronary artery disease
  • Liver function impairment
  • Renal function impairment
  • History of intestinal surgery
  • Chronic hypoxic diseases (emphysema and cor pulmonale)
  • Infectious disease
  • Hematological disease
  • Systemic inflammatory disease
  • Cancer
  • Pregnant
  • Ingesting agents known to influence glucose or lipid metabolism;
  • Any antibiotics or probiotics in the past three months prior to the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    sitagliptin

    sitagliptin 100mg

    Drug: Sitagliptin 100mg

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c change

    Changes in HbA1c from baseline at 1 month and 3 months during follow-up

    Time frame: Changes in HbA1c from baseline at 1 month and 3 months during follow-up

Secondary outcomes

  1. fasting blood glucose change

    Changes in fasting blood glucose from baseline at 1 month and 3 months during follow-up

    Time frame: Changes in fasting blood glucose from baseline at 1 month and 3 months during follow-up

  2. HOMA-IR change

    Changes in HOMA-IR from baseline at 1 month and 3 months during follow-up

    Time frame: Changes in HOMA-IR from baseline at 1 month and 3 months during follow-up

  3. Glycated Albumin(GSA)change

    Changes in Glycated Albumin from baseline at 1 month and 3 months during follow-up

    Time frame: Changes in Glycated Albumin from baseline at 1 month and 3 months during follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang Q, Ma L, Zhang Y, Zhang L, An Y, Liu J, Wang G. Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Diabetes Ther. 2021 Apr;12(4):1029-1039. doi: 10.1007/s13300-021-01023-z. Epub 2021 Feb 24. PubMed 33625721 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jun 2025, 65 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 65 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2020
First posted
Aug 3, 2020
StartActual
Jan 1, 2020
Primary completionEst.
Jun 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04495881
Responsible party
Guang Wang (Professor and Director, Department of Endocrinology, Beijing Chao Yang Hospital) — Principal investigator
First posted
Aug 3, 2020
Start date
Jan 1, 2020
Primary completion
Jun 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Jul 28, 2023

Study contacts

Jia Liu, MD
Contact
liujia0116@126.com
010-85231710
Yan Duan, MD
Contact
010-85231711
Guang Wang, MD
principal investigator · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion